Literature DB >> 25035943

Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa.

Amrita Daftary1, Nesri Padayatchi, Max O'Donnell.   

Abstract

Adherence to antiretroviral therapy (ART) and second-line antituberculosis medications is essential to achieve successful outcomes among individuals co-infected with HIV and multi or extensively drug-resistant TB (M/XDR-TB). In 2012-2013, we designed a qualitative study to explore barriers to adherence in KwaZulu-Natal, South Africa. We conducted six focus groups comprising 23 adults receiving treatment for either MDR-TB (n = 2) or XDR-TB (n = 21); 17 were on concurrent ART. Participants expressed a preference for ART over M/XDR-TB treatment as a result of greater tolerability, lower pill burden and a commitment to ART. Treatment outcomes and the social morbidity associated with M/XDR-TB, characterised by public notification, stigma and social isolation, were perceived to be worse than with HIV. Poor communication, low patient involvement and provider supervision of treatment exacerbated participants' negative experiences with TB care. To improve adherence, it is critical that new regimens for drug-resistant TB be developed with better efficacy, lower pill burden and fewer adverse effects. For the first time, such improved regimens are on the horizon. In parallel and equally important is the implementation of a cohesive approach that promotes patient involvement, empowerment and treatment literacy for HIV and for TB.

Entities:  

Keywords:  HIV/AIDS; adherence; co-infection; drug-resistant tuberculosis; qualitative methods

Mesh:

Substances:

Year:  2014        PMID: 25035943      PMCID: PMC4198425          DOI: 10.1080/17441692.2014.934266

Source DB:  PubMed          Journal:  Glob Public Health        ISSN: 1744-1692


  14 in total

1.  Adherence to medication regimens among low-income patients with multiple comorbid chronic conditions.

Authors:  Shiraz I Mishra; Deborah Gioia; Saltanat Childress; Beth Barnet; Ramothea L Webster
Journal:  Health Soc Work       Date:  2011-11

2.  Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance.

Authors:  Edward M Gardner; Shweta Sharma; Grace Peng; Katherine Huppler Hullsiek; William J Burman; Rodger D Macarthur; Margaret Chesney; Edward E Telzak; Gerald Friedland; Sharon B Mannheimer
Journal:  AIDS       Date:  2008-01-02       Impact factor: 4.177

3.  HIV and tuberculosis in Durban, South Africa: adherence to two medication regimens.

Authors:  Inge B Corless; Dean Wantland; Busi Bhengu; Patricia McInerney; Busi Ncama; Patrice K Nicholas; Chris McGibbon; Emily Wong; Sheila M Davis
Journal:  AIDS Care       Date:  2009-09

4.  Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting.

Authors:  N R Gandhi; J R Andrews; J C M Brust; R Montreuil; D Weissman; M Heo; A P Moll; G H Friedland; N S Shah
Journal:  Int J Tuberc Lung Dis       Date:  2012-01       Impact factor: 2.373

5.  Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study.

Authors:  Elize Pietersen; Elisa Ignatius; Elizabeth M Streicher; Barbara Mastrapa; Xavier Padanilam; Anil Pooran; Motasim Badri; Maia Lesosky; Paul van Helden; Frederick A Sirgel; Robin Warren; Keertan Dheda
Journal:  Lancet       Date:  2014-01-17       Impact factor: 79.321

6.  A qualitative exploration of multiple medicines beliefs in co-morbid diabetes and cardiovascular disease.

Authors:  R J Stack; R A Elliott; P R Noyce; C Bundy
Journal:  Diabet Med       Date:  2008-10       Impact factor: 4.359

Review 7.  HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response.

Authors:  Salim S Abdool Karim; Gavin J Churchyard; Quarraisha Abdool Karim; Stephen D Lawn
Journal:  Lancet       Date:  2009-08-24       Impact factor: 79.321

Review 8.  Patient empowerment in tuberculosis control: reflecting on past documented experiences.

Authors:  Jean Macq; Ted Torfoss; Haileyesus Getahun
Journal:  Trop Med Int Health       Date:  2007-07       Impact factor: 2.622

Review 9.  Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings.

Authors:  Stephen D Lawn; Katharina Kranzer; Robin Wood
Journal:  Clin Chest Med       Date:  2009-12       Impact factor: 2.878

10.  Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection.

Authors:  Max R O'Donnell; Nesri Padayatchi; Charlotte Kvasnovsky; Lise Werner; Iqbal Master; C Robert Horsburgh
Journal:  Emerg Infect Dis       Date:  2013-03       Impact factor: 6.883

View more
  32 in total

1.  "It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.

Authors:  Karen B Jacobson; Linda Niccolai; Nonhle Mtungwa; Anthony P Moll; Sheela V Shenoi
Journal:  AIDS Care       Date:  2017-02-01

2.  Care of the patient with XDR-TB who has failed treatment.

Authors:  Karen Blake Jacobson; Matthew Tate; Francois Eksteen; Anthony Moll; Nesri Padayatchi; Gerald Friedland; Sheela Shenoi
Journal:  Lancet Respir Med       Date:  2015-04       Impact factor: 30.700

3.  Treatment Adherence Among Persons Receiving Concurrent Multidrug-Resistant Tuberculosis and HIV Treatment in KwaZulu-Natal, South Africa.

Authors:  Fay Stephens; Neel R Gandhi; James C M Brust; Koleka Mlisana; Pravi Moodley; Salim Allana; Angie Campbell; Sarita Shah
Journal:  J Acquir Immune Defic Syndr       Date:  2019-10-01       Impact factor: 3.731

4.  Improving outcomes for multi-drug-resistant tuberculosis in the Peruvian Amazon - a qualitative study exploring the experiences and perceptions of patients and healthcare professionals.

Authors:  Thomas W McNally; Gilles de Wildt; Graciela Meza; Connie M D Wiskin
Journal:  BMC Health Serv Res       Date:  2019-08-22       Impact factor: 2.655

5.  Electronic Dose Monitoring Identifies a High-Risk Subpopulation in the Treatment of Drug-resistant Tuberculosis and Human Immunodeficiency Virus.

Authors:  Jennifer R Zelnick; Amrita Daftary; Christina Hwang; Amy S Labar; Resha Boodhram; Bhavna Maharaj; Allison K Wolf; Shinjini Mondal; K Rivet Amico; Catherine Orrell; Boitumelo Seepamore; Gerald Friedland; Nesri Padayatchi; Max R O'Donnell
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

6.  A new era for treatment of drug-resistant tuberculosis.

Authors:  Neel R Gandhi; James C M Brust; N Sarita Shah
Journal:  Eur Respir J       Date:  2018-10-04       Impact factor: 16.671

7.  Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV.

Authors:  M R O'Donnell; A Daftary; M Frick; Y Hirsch-Moverman; K R Amico; M Senthilingam; A Wolf; J Z Metcalfe; P Isaakidis; J L Davis; J R Zelnick; J C M Brust; N Naidu; M Garretson; D R Bangsberg; N Padayatchi; G Friedland
Journal:  Int J Tuberc Lung Dis       Date:  2016-04       Impact factor: 2.373

8.  Training social workers to enhance patient-centered care for drug-resistant TB-HIV in South Africa.

Authors:  J R Zelnick; B Seepamore; A Daftary; K R Amico; X Bhengu; G Friedland; N Padayatchi; K Naidoo; M R O'Donnell
Journal:  Public Health Action       Date:  2018-03-21

9.  To End TB, First-Ever High-Level Meeting on Tuberculosis Must Address Stigma.

Authors:  Amrita Daftary; Ellen M H Mitchell; Michael J A Reid; Endalkachew Fekadu; Eric Goosby
Journal:  Am J Trop Med Hyg       Date:  2018-11       Impact factor: 2.345

10.  Prevalence of drug-resistant tuberculosis in Zimbabwe: A health facility-based cross-sectional survey.

Authors:  Collins Timire; John Z Metcalfe; Joconiah Chirenda; Jerod N Scholten; Barbara Manyame-Murwira; Mkhokheli Ngwenya; Ronnie Matambo; Kelvin Charambira; Herbert Mutunzi; Nico Kalisvaart; Charles Sandy
Journal:  Int J Infect Dis       Date:  2019-07-27       Impact factor: 12.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.